(Q37832752)

24 August 2017

1 reference

title

Intramuscular extended-release naltrexone: current evidence (English)

1 reference

24 August 2017

0 references

David R Gastfriend

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

Annals of the New York Academy of Sciences

24 August 2017

published in

1 reference

24 August 2017

volume

1216

1 reference

24 August 2017

page(s)

144-166

1 reference

The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Mortality and morbidity attributable to use of addictive substances in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Alcohol and public health

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

India: alcohol and public health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Syntheses of novel high affinity ligands for opioid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Alteration of ethanol self-administration by naltrexone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Naltrexone-induced alterations in human ethanol intoxication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Effect of naltrexone on alcohol "high" in alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Datapoints: Trends in naltrexone use among members of a large private health plan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Biodegradation and biocompatibility of PLA and PLGA microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

The preclinical development of Medisorb Naltrexone, a once a month long acting injection, for the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Physician substance abuse and recovery: what does it mean for physicians--and everyone else?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Quality of life in alcohol-dependent subjects--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Concurrent validity of the Alcohol Use Disorders Identification Test (AUDIT) and AUDIT zones in defining levels of severity among out-patients with alcohol dependence in the COMBINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Tobacco use is associated with more severe alcohol dependence, as assessed by the number of DSM-IV criteria, in Swedish male type 1 alcoholics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Association between psychiatric symptoms and severity of alcohol dependence in a sample of brazilian men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

The role of alcoholic beverage preference in the severity of alcohol dependence and adherence to the treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Nucleus accumbens opioid, GABAergic, and dopaminergic modulation of palatable food motivation: Contrasting effects revealed by a progressive ratio study in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Monoamine levels in the nucleus accumbens correlate with male sexual behavior in middle-aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Opiate receptor blockade by naltrexone and mood state after acute physical activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Opioid peptides and the control of human ingestive behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Extended-release naltrexone for treatment of alcohol dependence in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Long-acting injectable naltrexone for the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Brain dopamine and reward

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Effects of naltrexone on the subjective response to amphetamine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Adoption of naltrexone to treat alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Impact of treatment with intramuscular, injectable, extended-release naltrexone on counseling and support group participation in patients with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

Opioid Antagonists in the Treatment of Impulse-Control Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.2010.05900.X

10.1111/J.1749-6632.2010.05900.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference